Drug Trial Radar · NCT07048197
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Jun 20, 2025
Primary completion
Nov 1, 2028
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease
Conditions
- Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Interventions
Rapcabtagene autoleucelBiological
Single infusion of Rapcabtagene autoleucel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 24 months
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Göttingen, Lower Saxony, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.